Search Results

The impact of antipsychotic agent choice on the risk of coronary heart disease mortality due to cholesterol effects.

• Authors : Coleman, Craig I.; White, C. Michael

Subjects: ANTIPSYCHOTIC agents; PSYCHIATRIC drugs; CORONARY disease

• Source: Formulary. Jan2007, Vol. 42 Issue 1, p62-65. 4p.

Record details

Coronary heart disease: Primary and secondary prevention.

• Authors : Brenner, Michael; Butcher, Allison

Subjects: PHARMACY research; CORONARY heart disease prevention; CORONARY heart disease risk factorsUNITED States

• Source: Drug Topics. Dec2009, Vol. 153 Issue 12, p50-58. 9p.

Record details

ACE inhibitors versus ARBs for ischemic heart disease: comparative effectiveness.

Subjects: CORONARY heart disease treatment; ACE inhibitors; ANGIOTENSIN II

• Source: Formulary. Jan2010, Vol. 45 Issue 1, p15-15. 1p.

Record details

Evidence supports high-dose over low-dose atorvastatin in stable coronary heart disease.

Subjects: CORONARY heart disease treatment; DOSE-response relationship in biochemistry; DRUG efficacy

• Source: Formulary. May2005, Vol. 40 Issue 5, p158-158. 1/2p.

Record details

One quarter of heart disease deaths are preventable.

Subjects: HEART disease related mortality; PREVENTION of heart diseases; BEHAVIOR modification

• Source: Formulary. Oct2013, Vol. 48 Issue 10, p313-313. 1/3p.

Record details

Graded relationship demonstrated between statins' effects on mortality and patients' coronary heart disease risk.

• Authors : Mehta, J. L.; Bursac, Z.; Hauer-Jensen, M.

Subjects: STATINS (Cardiovascular agents); CARDIOVASCULAR agents; CORONARY disease

• Source: Formulary. Jan2007, Vol. 42 Issue 1, p33-36. 2p.

Record details

Statin therapy reduces severity of second ischemic stroke in patients with no history of coronary heart disease.

Subjects: STATINS (Cardiovascular agents); THERAPEUTICS; CORONARY disease

• Source: Formulary. Nov2006, Vol. 41 Issue 11, p592-595. 2p.

Record details

FDA Approves Leqvio for Earlier Use in Heart Disease.

Subjects: MYOCARDIAL infarction risk factors; DRUG therapy for heart diseases; ANTILIPEMIC agents

• Source: Formulary Watch. 7/10/2023, p1-1. 1p.

Record details

Partnerships for Cardiac Safety.

• Authors : Zywietz, Tosja K.^1,2

• Source: Applied Clinical Trials. Apr2009 Supplement, p24-28. 3p.

Record details

Ticagrelor: An oral, non-thienopyridine P2Y12 receptor antagonist for the treatment of acute coronary syndromes.

• Authors : Jennings, Douglas L.

Subjects: PLATELET aggregation inhibitors; CORONARY heart disease treatment; DRUG efficacy

• Source: Formulary. May2010, Vol. 45 Issue 5, p148-154. 6p.

Record details